<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Molecular pathogenesis of diffuse gliomas
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Molecular pathogenesis of diffuse gliomas
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Molecular pathogenesis of diffuse gliomas
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Tracy Batchelor, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David N Louis, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Patrick Y Wen, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            April F Eichler, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 16, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gliomas are primary brain tumors that display histologic features of glial cells (ie, astrocytes, oligodendrocytes, and ependymal cells). The diffuse gliomas are the most common types and generally affect the cerebral hemispheres of adults. They are classified based upon their molecular features as well as their line of differentiation and are graded according to their histologic degree of malignancy and their molecular characteristics.
        </p>
        <p>
         Diffuse gliomas in adults are classified according to the World Health Organization (WHO) system by both histologic and molecular characteristics as isocitrate dehydrogenase (IDH)-mutant or IDH-wildtype astrocytomas; IDH-mutant and 1p/19q-codeleted oligodendrogliomas; and IDH-wildtype glioblastomas  (
         <a class="graphic graphic_algorithm graphicRef134946" href="/z/d/graphic/134946.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid1">
          1,2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5211.html" rel="external">
          "Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors"
         </a>
         .)
        </p>
        <p>
         The pathogenesis and biology of diffuse gliomas are reviewed here. The pathologic diagnosis, clinical manifestations, diagnosis, and treatment of these tumors are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5211.html" rel="external">
          "Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5228.html" rel="external">
          "Clinical presentation, diagnosis, and initial surgical management of high-grade gliomas"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5225.html" rel="external">
          "Radiation therapy for high-grade gliomas"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5207.html" rel="external">
          "Initial treatment and prognosis of IDH-wildtype glioblastoma in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H703112">
         <span class="h1">
          CELL OF ORIGIN
         </span>
         <span class="headingEndMark">
          —
         </span>
         High-grade gliomas likely arise from neural progenitor cells, but the precise stage of differentiation of such target cells (ie, stem cells versus progenitor cells) has not been clear. In isocitrate dehydrogenase (IDH)-wildtype glioblastoma, mouse models and molecular genetic studies of patient tumor tissue, adjacent subventricular zone (SVZ) biopsies, and normal tissue suggest that astrocyte-like neural stem cells in the SVZ, which contain low-level somatic driver mutations, are the cell of origin [
         <a href="#rid3">
          3
         </a>
         ]. Over time these cells may migrate and acquire additional somatic mutations, ultimately leading to the development of IDH-wildtype glioblastoma in distant brain regions.
        </p>
        <p>
         High-grade gliomas contain multipotent tumor stem cells that are responsible for populating and repopulating the tumors [
         <a href="#rid4">
          4-7
         </a>
         ]. The existence of these tumor stem cells may have therapeutic implications, since therapies that do not ablate the tumor stem cells will be ineffective in eradicating the tumor.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          ADULT DIFFUSE GLIOMAS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Understanding of the molecular genetic basis of high-grade gliomas has increased markedly over the last three decades [
         <a href="#rid8">
          8-11
         </a>
         ]. This knowledge has provided insight into the biologic basis of high-grade glioma formation and progression. This information has permitted the generation of novel genetically engineered murine models of diffuse high-grade glioma [
         <a href="#rid12">
          12-14
         </a>
         ]. Some of these molecular changes may represent potential targets for future gene or molecular pharmacologic therapies. However, single-agent therapeutic approaches may be confounded by the sometimes remarkable heterogeneity within individual high-grade gliomas, which has been demonstrated at the regional, cellular, and molecular levels [
         <a href="#rid15">
          15-17
         </a>
         ].
        </p>
        <p>
         As with other human cancers, the formation and progression of diffuse gliomas is accompanied by activation of oncogenes, inactivation of tumor suppressor genes, abrogation of apoptotic genes, and deregulation of DNA repair genes, as well as extensive epigenetic alterations. Different constellations of genetic and epigenetic alterations are associated with specific types of high-grade gliomas, with particular tumor grades, and with differential sensitivities to specific therapies [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Formation of astrocytoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         The formation of World Health Organization (WHO) grade 2 astrocytoma is associated with at least three moderately common genetic alterations: heterozygous point mutations in isocitrate dehydrogenase 1 (
         <em>
          IDH1
         </em>
         ) or less commonly
         <em>
          IDH2
         </em>
         ; mutations in the chromatin regulator gene,
         <em>
          ATRX
         </em>
         ; and inactivation of the
         <em>
          TP53
         </em>
         tumor suppressor gene  (
         <a class="graphic graphic_table graphicRef134980" href="/z/d/graphic/134980.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H15072634">
         <span class="h3">
          Isocitrate dehydrogenase (IDH) gene
         </span>
         <span class="headingEndMark">
          —
         </span>
         Somatic mutations affecting the active site of the Krebs cycle enzyme IDH1 were first identified in glioma in 2008 as part of a genomic analysis of human glioblastoma tumor samples, in which 18 out of 149 tumors (12 percent) contained alterations in
         <em>
          IDH1
         </em>
         , primarily at the R132 residue [
         <a href="#rid19">
          19
         </a>
         ]. Subsequent studies have confirmed these findings, identified rarer mutations in
         <em>
          IDH1
         </em>
         and the related gene
         <em>
          IDH2
         </em>
         in glioma, and extended the spectrum of involved tumors to include a much greater proportion of lower-grade gliomas than glioblastoma [
         <a href="#rid20">
          20
         </a>
         ]. Such mutations are the earliest known events in diffuse gliomagenesis [
         <a href="#rid19">
          19,21
         </a>
         ].
        </p>
        <p>
         A number of putative mechanisms have been suggested for IDH dysregulation in glioma formation:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Heterozygous mutations in
         <em>
          IDH1
         </em>
         foster the formation of an oncogenic metabolite, R(-)-2-hydroxyglutarate (2HG) [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In leukemias, IDH mutation and 2HG production have been linked via DNA methylation changes to impaired hematopoietic cell differentiation [
         <a href="#rid23">
          23
         </a>
         ]. Similarly, in IDH-mutant gliomas, epigenetic dysregulation mediated by 2HG results in a CpG island methylator phenotype [
         <a href="#rid24">
          24,25
         </a>
         ]. The functional importance of this phenotype in early glioma formation may relate in part to changes in insulator protein binding, resulting in aberrant activation of oncogenes such as platelet-derived growth factor receptor alpha (
         <em>
          PDGFRA)
         </em>
         [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         2HG accumulation has paracrine effects on T cells in the glioma microenvironment, which may alter T cell activation and impair host antitumor immunity [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         IDH1 mutant enzymes may act as dominant-negative inhibitors of wildtype IDH1 enzymatic function, exerting a tumorigenic effect through induction of the hypoxia-inducible factor 1 (HIF-1) alpha pathway [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         By definition,
         <em>
          IDH1
         </em>
         or
         <em>
          IDH2
         </em>
         mutations are present in all IDH-mutant astrocytic tumors and all oligodendrogliomas  (
         <a class="graphic graphic_algorithm graphicRef134946" href="/z/d/graphic/134946.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid1">
          1,2
         </a>
         ].
         <em>
          IDH1/2
         </em>
         mutations in glioma are associated with significantly prolonged progression-free and overall survival compared with most histologically comparable tumors without an IDH mutation [
         <a href="#rid29">
          29-32
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5186.html" rel="external">
          "Clinical features, diagnosis, and pathology of IDH-mutant, 1p/19q-codeleted oligodendrogliomas"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5198.html" rel="external">
          "Treatment and prognosis of IDH-mutant astrocytomas in adults", section on 'Prognosis'
         </a>
         .)
        </p>
        <p>
         The presence of IDH
         <em>
         </em>
         mutations also appears to be useful for distinguishing diffuse astrocytoma from reactive astrocytosis (gliosis), particularly in biopsy specimens. (See
         <a class="medical medical_review" href="/z/d/html/5211.html" rel="external">
          "Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors", section on 'IDH1/IDH2 mutation'
         </a>
         .)
        </p>
        <p>
         Targeted inhibitors of mutant IDH1 are in development, having shown evidence of delayed growth and promotion of cell differentiation in glioma cell lines. A mutation-specific vaccine is also under investigation. (See
         <a class="medical medical_review" href="/z/d/html/5221.html" rel="external">
          "Treatment and prognosis of IDH-mutant, 1p/19q-codeleted oligodendrogliomas in adults", section on 'Investigational IDH-targeted approaches'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H67101883">
         <span class="h3">
          <i>
           ATRX
          </i>
          gene
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mutations in the chromatin regulator gene, alpha-thalassemia/mental retardation syndrome X-linked (
         <em>
          ATRX
         </em>
         ), are a marker for astrocytic lineage in diffuse gliomas.
        </p>
        <p>
         Missense mutations in
         <em>
          ATRX
         </em>
         are present in over 70 percent of WHO grade 2 and 3 IDH-mutant astrocytomas [
         <a href="#rid20">
          20,33-35
         </a>
         ].
         <em>
          ATRX
         </em>
         is a switch/sucrose nonfermentable (SWI/SNF) helicase that plays a key role in assisting H3.3 chromatin deposition in telomeric regions, and
         <em>
          ATRX
         </em>
         mutations show a close correlation with an alternative lengthening of telomeres (ALT) phenotype [
         <a href="#rid36">
          36
         </a>
         ]. Mutations likely represent an early event in gliomagenesis, providing a genetic mechanism responsible for telomere maintenance.
        </p>
        <p>
         <em>
          ATRX
         </em>
         mutations are closely correlated with
         <em>
          IDH1/2
         </em>
         and
         <em>
          TP53
         </em>
         mutations and are mutually exclusive with 1p/19q codeletion, the molecular hallmark of oligodendroglioma [
         <a href="#rid10">
          10,33-35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H833498887">
         <span class="h3">
          <i>
           TP53
          </i>
          gene
         </span>
         <span class="headingEndMark">
          —
         </span>
         Early involvement of the tumor suppressor
         <em>
          TP53
         </em>
         in astrocytomas has been known for decades and confirmed by next-generation sequencing studies.
        </p>
        <p>
         <em>
          TP53
         </em>
         maps to chromosome 17p and it encodes the p53 protein, which has an integral role in a number of cellular processes, including cell cycle arrest, response to DNA damage, and apoptosis. Inactivation of the
         <em>
          TP53
         </em>
         gene, usually due to mutation of one copy and chromosomal loss of the remaining allele, occurs in both IDH-mutant astrocytomas and IDH-wildtype glioblastomas [
         <a href="#rid9">
          9,37
         </a>
         ], with the large majority of IDH-mutant astrocytomas harboring
         <em>
          TP53
         </em>
         mutations [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
         The
         <em>
          TP53
         </em>
         mutations are primarily missense mutations and target the evolutionarily conserved domains in exons 5, 7, and 8. Particular mutational hot spots include codons 175, 248, and 273, in which C to T transitions are most likely the result of spontaneous deamination of 5-methylcytosine residues. These mutations affect p53 residues that are crucial for DNA binding, presumably leading to loss of p53-mediated function [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         <em>
          TP53
         </em>
         also plays a role in protecting cells from DNA damage. Mutations of
         <em>
          TP53
         </em>
         may therefore lead to tumor progression through genomic instability [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H67101302">
         <span class="h2">
          Formation of oligodendroglial tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Simultaneous loss of chromosomes 1p and 19q is a defining molecular feature of oligodendrogliomas, presumably on the basis of a single translocation event [
         <a href="#rid38">
          38,39
         </a>
         ]. Loss of 1p/19q occurs in the setting of
         <em>
          IDH1/2
         </em>
         mutation, suggesting that the chromosomal losses follow the
         <em>
          IDH1/2
         </em>
         mutations.
        </p>
        <p>
         Codeletion of 1p and 19q in oligodendroglioma has suggested that these chromosomal arms may contain tumor suppressor genes, and several candidate genes have been identified. Mutations of the capicua transcriptional repressor (
         <em>
          CIC
         </em>
         ) gene on chromosome 19q13.2 have been found in 70 percent of oligodendrogliomas with 1p/19q codeletion and are thus correlated with IDH mutations [
         <a href="#rid33">
          33,40,41
         </a>
         ], but the functional significance of mutations in this gene remains unclear. Similarly, mutations in far upstream element binding protein 1 (
         <em>
          FUBP1
         </em>
         ) on chromosome 1p have been observed in some oligodendrogliomas, although at a lower frequency than
         <em>
          CIC
         </em>
         alterations.
        </p>
        <p>
         Telomere expression may also play a role in the pathogenesis of oligodendroglioma, but in a manner distinct from the
         <em>
          ATRX
         </em>
         pathway that has been implicated in astrocytoma. Point mutations in the telomerase reverse transcriptase (
         <em>
          TERT
         </em>
         ) gene promoter are present in the great majority of oligodendrogliomas, leading to increased telomerase expression [
         <a href="#rid42">
          42,43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Formation of glioblastoma and transition from low-grade to high-grade glioma
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the past, tumors termed "glioblastoma" had been divided into those that arose de novo ("primary") and those that arose in the setting of lower-grade astrocytic gliomas ("secondary"). However, as of the 2021 WHO classification, "glioblastomas" are defined as being IDH-wildtype; the majority of these tumors would have been termed "primary glioblastomas" in the prior literature [
         <a href="#rid1">
          1,2
         </a>
         ]. By contrast, the IDH-mutant astrocytomas that progress to WHO grade 4 lesions are the tumors that would have been termed "secondary glioblastoma" in the past.
        </p>
        <p>
         There is nonetheless overlap in the genetic features associated with higher-grade diffuse gliomas. For example, IDH-wildtype glioblastomas and the transition from lower- to higher-grade IDH-mutant gliomas are associated with a variety of generally common molecular alterations, including cell cycle checkpoint inactivation, tumor suppressor gene inactivation, and angiogenesis. Early molecular alterations, including
         <em>
          IDH1/2
         </em>
         mutations, tend to be retained at progression, and a subset of tumors treated with alkylating chemotherapy develop a hypermutation phenotype [
         <a href="#rid44">
          44,45
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15072833">
         <span class="h3">
          Checkpoint alterations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Loss of chromosome 13q, which includes the retinoblastoma (
         <em>
          RB
         </em>
         ) gene locus, occurs in approximately one-third of higher-grade astrocytic tumors [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         One of the major pathways controlling the G1-S phase cell cycle checkpoint involves the p16, cyclin dependent kinase (CDK)-4, cyclin D, and pRB (retinoblastoma) proteins [
         <a href="#rid18">
          18
         </a>
         ]. Alterations of at least one component of this pathway occur in many higher-grade astrocytomas and in the vast majority of glioblastomas. The protein encoded by the
         <em>
          RB
         </em>
         gene, pRB, is important in cell-cycle arrest; the loss of pRB function in gliomas thereby removes an important brake on the cell cycle.
        </p>
        <p>
         One upstream mediator of pRB function is the p16 product of the
         <em>
          CDKN2A
         </em>
         gene (also called
         <em>
          p16INK4A
         </em>
         ) on chromosome 9p, a tumor suppressor inactivated in a number of human tumors. p16 inhibits the cyclin-cyclin dependent kinase complex that regulates pRB. The vast majority of glioma cell lines and two-thirds of high-grade astrocytic gliomas show homozygous deletions of chromosome 9p that include this gene. It is likely that these deletions result in loss of expression of the p16 and p14ARF transcripts from
         <em>
          CDKN2A
         </em>
         and the p15 transcript from the nearby
         <em>
          CDKN2B
         </em>
         (also called multiple tumor suppressor 2 [
         <em>
          MTS2
         </em>
         ]), resulting in loss of multiple cell cycle control checkpoints and greater proliferation [
         <a href="#rid18">
          18
         </a>
         ]. Homozygous deletion of the
         <em>
          CDKN2A
         </em>
         gene is a predictor of worse behavior in IDH-mutant astrocytic gliomas [
         <a href="#rid1">
          1,2,46
         </a>
         ].
        </p>
        <p>
         The cyclin dependent kinase 4 (
         <em>
          CDK4
         </em>
         ) gene is amplified and overexpressed in 10 to 15 percent of high-grade gliomas.
         <em>
          CDK4
         </em>
         itself is regulated by p16 and inactivates pRB through phosphorylation. Thus, nearly all high-grade tumors have impairments of this single critical cell cycle control pathway. It is likely as well that less profound defects in cell cycle regulation occur in lower-grade gliomas; for instance,
         <em>
          TP53
         </em>
         gene mutations may affect both the G1-S and G2-M checkpoints.
        </p>
        <p>
         In general, alterations of
         <em>
          RB
         </em>
         ,
         <em>
          CDKN2A
         </em>
         and the
         <em>
          CDK4
         </em>
         gene are inversely related in high-grade astrocytomas and glioblastoma [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15072839">
         <span class="h3">
          <i>
           PTEN
          </i>
          inactivation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Malignant gliomas such as glioblastoma are also associated with inactivation of the phosphatase and tensin homolog (
         <em>
          PTEN
         </em>
         ) tumor suppressor gene on chromosome 10 [
         <a href="#rid48">
          48
         </a>
         ]. Chromosome 10 loss occurs in 60 to 85 percent of glioblastomas, with approximately 25 percent of cases having
         <em>
          PTEN
         </em>
         mutations [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1698586851">
         <span class="h3">
          <i>
           TERT
          </i>
          promoter mutation
         </span>
         <span class="headingEndMark">
          —
         </span>
         IDH-wildtype glioblastomas are also associated with mutations of the
         <em>
          TERT
         </em>
         gene promoter [
         <a href="#rid43">
          43
         </a>
         ], consistent with a role of telomere maintenance in glioblastoma biology. This role is supported by the observation that a
         <em>
          TERT
         </em>
         promoter mutation in a histologically lower-grade IDH-wildtype astrocytic glioma is associated with grade 4 behavior and a diagnosis of IDH-wildtype glioblastoma [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2008651">
         <span class="h3">
          Growth factor amplification and overexpression
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of growth factors, or oncogenes, are amplified and/or overexpressed in high-grade gliomas and thus provide a growth advantage to neoplastic cells. In general, glioma cells express both the ligand growth factor and its receptor, setting up an autocrine growth-promoting loop. Some growth factors are highly expressed in low-grade as well as high-grade gliomas, whereas others are primarily overexpressed only in glioblastomas. Those involved in high-grade glioma include [
         <a href="#rid18">
          18
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Platelet-derived growth factor (PDGF)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Epidermal growth factor receptor (EGFR)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Met proto-oncogene/hepatocyte growth factor receptor (MET)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basic fibroblast growth factor (bFGF, FGF-2) and fibroblast growth factor receptors (FGFR1, FGFR3)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Transforming growth factor (TGF)-alpha
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Insulin-like growth factor (IGF)-1
        </p>
        <p>
        </p>
        <p>
         Of these, EGFR and PDGF have been most studied. Amplification of the
         <em>
          EGFR
         </em>
         gene is associated with higher-grade tumors. Amplification is found in approximately 40 percent of all glioblastomas, resulting in overexpression of EGFR, a transmembrane receptor tyrosine kinase [
         <a href="#rid37">
          37
         </a>
         ]. Approximately one-third of glioblastomas with
         <em>
          EGFR
         </em>
         gene amplification also have gene rearrangements, some encoding truncated, constitutively active mutants; by far the most common of these is known as variant III (vIII) [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         Rarer examples of an oncogenic chromosomal translocation fusing the tyrosine kinase coding domains of
         <em>
          FGFR1
         </em>
         or
         <em>
          FGFR3
         </em>
         to transforming acidic coiled-coil 1 or 3 (
         <em>
          TACC1/3
         </em>
         ), mutually exclusive with
         <em>
          EGFR
         </em>
         ,
         <em>
          PDGFR,
         </em>
         or
         <em>
          MET
         </em>
         amplification, suggest a novel mechanism of aberrant signaling in glioblastoma [
         <a href="#rid50">
          50,51
         </a>
         ].
        </p>
        <p>
         The wingless (WNT) signaling pathway may also be aberrant in glioblastoma, possibly playing a role in glioblastoma stem-like cell self-renewal [
         <a href="#rid52">
          52
         </a>
         ]. Aberrant WNT pathway signaling is also implicated in a subset of medulloblastomas. (See
         <a class="medical medical_review" href="/z/d/html/5218.html" rel="external">
          "Histopathology, genetics, and molecular groups of medulloblastoma", section on 'Wnt pathway'
         </a>
         .)
        </p>
        <p>
         The potential therapeutic implications of these and other changes in glioblastoma are the subject of ongoing investigation.
        </p>
        <p class="headingAnchor" id="H15072966">
         <span class="h3">
          Angiogenesis
         </span>
         <span class="headingEndMark">
          —
         </span>
         A dramatic sequence of vascular changes occurs in the biology of glioblastoma, a fact that is reflected in the intense, almost ring-like contrast enhancement that surrounds rapidly growing tumors [
         <a href="#rid53">
          53
         </a>
         ]. High-grade gliomas are highly vascular tumors, and the histologic presence of microvascular proliferation nearly always indicates that a diffuse glioma is of high grade. Angiogenic molecules have been found in high-grade gliomas, primarily in glioblastomas [
         <a href="#rid9">
          9,53
         </a>
         ]. The most clearly implicated is vascular endothelial growth factor (VEGF), an endothelial cell mitogen that is expressed most often adjacent to areas of necrosis but not in lower-grade astrocytomas.
        </p>
        <p>
         VEGF receptors are expressed by tumor endothelial cells, setting up a paracrine loop in which the tumor cells encourage vascular proliferation. The microenvironment is thus of importance in glioblastoma, with regions of neovascularization often surrounding zones of necrosis. Other proangiogenic signal transduction pathways are also upregulated in glioblastoma, including PDGF and its receptor on endothelial cells, PDGFR-beta; angiopoietin-2 and its receptor Tie-2; the family of fibroblast growth factors and receptors; and stromal-cell derived factor-one alpha.
        </p>
        <p>
         One of the main triggers for tumor-related angiogenesis is believed to be the physiologic response to hypoxia, which induces increased transcription of the
         <em>
          VEGF
         </em>
         gene by the hypoxia-inducible factor (HIF) family of transcription factors [
         <a href="#rid54">
          54-56
         </a>
         ]. An intriguing hypothesis suggests that thrombosis of small blood vessels, perhaps mediated by tissue factor, induces micronecrosis and that these events initiate the hypoxic and angiogenic cascades [
         <a href="#rid54">
          54,55
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2794.html" rel="external">
          "Overview of angiogenesis inhibitors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2008511">
         <span class="h3">
          Treatment effects and hypermutation phenotype
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many gliomas treated with alkylating agent chemotherapy develop additional genetic alterations, termed a hypermutation phenotype. One mechanism for such hypermutation is inactivation of mismatch repair (MMR) genes [
         <a href="#rid45">
          45,57,58
         </a>
         ].
        </p>
        <p>
         A hypermutation phenotype in recurrent gliomas has been described in approximately one-quarter to one-half of recurrent gliomas with prior exposure to
         <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">
          temozolomide
         </a>
         chemotherapy [
         <a href="#rid59">
          59-62
         </a>
         ]. The phenotype appears to be much less common after exposure to nitrosoureas or radiation alone. Among diffuse glioma subtypes, IDH-mutant gliomas and those with O6-methylguanine-DNA methyltransferase (
         <em>
          MGMT
         </em>
         ) promoter methylation have the highest rates of treatment-associated hypermutation [
         <a href="#rid44">
          44,61
         </a>
         ]. There are conflicting data on whether the presence of a hypermutation phenotype in recurrent gliomas has an adverse impact on overall survival.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Genetic/epigenetic subsets of glioblastoma and other malignant gliomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         The current WHO classification restricts the diagnosis of glioblastoma to those highest-grade diffuse gliomas that are IDH-wildtype and uses a variety of genetic changes and methylome profiles to classify tumors  (
         <a class="graphic graphic_table graphicRef134980" href="/z/d/graphic/134980.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1,2
         </a>
         ]. In particular, glioblastoma is characterized by complex genetic and epigenetic landscapes, and such differences can be used to subdivide these tumors into diagnostic groups [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2008550">
         <span class="h3">
          Hypermethylation phenotype
         </span>
         <span class="headingEndMark">
          —
         </span>
         CpG island methylator phenotype may also provide another means to characterize glioblastomas. Analysis of tissue from a glioblastoma tumor tissue database identified a subset of tumors that were characterized by promoter hypermethylation at a large number of loci [
         <a href="#rid24">
          24
         </a>
         ]. Tumors containing this promoter hypermethylation were more commonly low grade and were observed in younger patients. These tumors were associated with
         <em>
          IDH1
         </em>
         mutations and a better prognosis compared with those without the hypermethylation phenotype [
         <a href="#rid29">
          29,30
         </a>
         ]. (See
         <a class="local">
          'Formation of astrocytoma'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H15072692">
         <span class="h3">
          Gene expression profile subtypes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Integrated analyses of gene expression profiles from large databases suggest that glioblastomas can be divided into proneural, neural, classical, and mesenchymal subtypes [
         <a href="#rid63">
          63
         </a>
         ]. To date, however, studies of genetic subsets of glioblastoma have revealed a few associations, but no clear clinically relevant correlations of genotype with tumor behavior [
         <a href="#rid64">
          64
         </a>
         ]. Moreover, single-cell analyses have shown that most glioblastomas have mixtures of cells, with mixed populations featuring many of these subtypes [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15072652">
         <span class="h1">
          PEDIATRIC DIFFUSE GLIOMAS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Significant insights into the molecular genetics of pediatric gliomas, as distinct from adult gliomas, have been gained through whole-genome sequencing studies of pediatric tumor specimens [
         <a href="#rid65">
          65
         </a>
         ], and pediatric-type diffuse gliomas are classified separately as of the 2021 WHO classification  (
         <a class="graphic graphic_table graphicRef134980" href="/z/d/graphic/134980.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1,2
         </a>
         ]. These are considered "pediatric-type" since, while they mostly occur in children, they are sometimes diagnosed in young adults.
        </p>
        <p class="headingAnchor" id="H15072659">
         <span class="h2">
          Pediatric-type diffuse low-grade gliomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite similar histopathology, adult-type and pediatric-type diffuse gliomas have different genetic underpinnings  (
         <a class="graphic graphic_table graphicRef134980" href="/z/d/graphic/134980.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         Duplication of the tyrosine kinase domain of the fibroblast growth factor receptor 1 (
         <em>
          FGFR1
         </em>
         ) gene is present in approximately one-quarter of pediatric-type diffuse gliomas [
         <a href="#rid65">
          65
         </a>
         ]. This duplication results in FGFR1 autophosphorylation and activation of downstream phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK/ERK) pathways.
         <em>
          FGFR1
         </em>
         is also subject to other genetic events at lower frequency, including
         <em>
          FGFR1-TACC1
         </em>
         and
         <em>
          FGFR3-TACC3
         </em>
         translocations, which have also been reported in rare cases of adult glioblastoma [
         <a href="#rid50">
          50,51
         </a>
         ].
        </p>
        <p>
         Additional genetic changes that have been observed in pediatric low-grade gliomas include rearrangements or amplifications affecting
         <em>
          MYB
         </em>
         or
         <em>
          MYBL1
         </em>
         , a variety of RAF pathway abnormalities, including
         <em>
          BRAF
         </em>
         fusions, and recurrent genetic events affecting histones and chromatin regulators [
         <a href="#rid66">
          66
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5202.html" rel="external">
          "Uncommon brain tumors", section on 'Pilocytic astrocytoma'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5229.html" rel="external">
          "Diffuse intrinsic pontine glioma", section on 'Molecular pathogenesis'
         </a>
         .)
        </p>
        <p>
         <em>
          BRAF
         </em>
         V600E point mutations, initially described in malignant melanoma, are commonly identified in lower-grade, circumscribed (ie, not “diffuse”) gliomas, including ganglioglioma, pleomorphic xanthoastrocytoma, and extra-cerebellar pilocytic astrocytoma. (See
         <a class="medical medical_review" href="/z/d/html/5211.html" rel="external">
          "Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors", section on 'Key molecular diagnostic tests'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15072673">
         <span class="h2">
          Pediatric-type diffuse high-grade gliomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pediatric high-grade gliomas also appear to have genetic alterations that are distinct from those observed in adult glioblastoma.
        </p>
        <p>
         Recurrent mutations in the
         <em>
          H3F3A
         </em>
         gene encoding histone H3.3 have been identified in approximately 30 percent of pediatric glioblastoma samples [
         <a href="#rid67">
          67,68
         </a>
         ]. Specific point mutations observed in this setting include K27M, G34R, and G34V. Mutations in the
         <em>
          ATRX-DAXX
         </em>
         complex, which mediates deposition of H3.3 in telomeric regions, were also identified in approximately 30 percent of these tumors [
         <a href="#rid67">
          67
         </a>
         ]. Subsequent studies have highlighted that distinct
         <em>
          H3F3A
         </em>
         mutations define epigenetic and clinicopathologic entities and are mutually exclusive with
         <em>
          IDH1
         </em>
         mutations [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
         Pediatric diffuse intrinsic pontine gliomas also commonly harbor H3 K27M mutations in either
         <em>
          H3F3A
         </em>
         or
         <em>
          HIST3BHI
         </em>
         , two of several genes encoding histone H3.1, as well as activating mutations in
         <em>
          ACVR1
         </em>
         . In the World Health Organization (WHO) classification, diffuse glial tumors of the brainstem, thalamus, or spinal cord with histone H3 K27M mutations are now termed "diffuse midline gliomas, H3 K27M-mutant." On the other hand, tumors with H3 G34 mutations are more often in the hemispheres of children and younger adults. (See
         <a class="medical medical_review" href="/z/d/html/5229.html" rel="external">
          "Diffuse intrinsic pontine glioma", section on 'Molecular pathogenesis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Classification
         </strong>
         – Gliomas are primary brain tumors that display histologic features of glial cells. Diffuse gliomas are classified according to the 2021 World Health Organization (WHO) system by both histologic and molecular characteristics as isocitrate dehydrogenase (IDH)-mutant astrocytomas, IDH-mutant and 1p/19q-codeleted oligodendrogliomas, and IDH-wildtype glioblastomas  (
         <a class="graphic graphic_table graphicRef134980" href="/z/d/graphic/134980.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef134946" href="/z/d/graphic/134946.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5211.html" rel="external">
          "Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diffuse astrocytoma formation
         </strong>
         – The formation of WHO grade 2 diffuse astrocytoma is associated with at least three moderately common and sometimes definitional genetic alterations: heterozygous point mutations in isocitrate dehydrogenase 1 (
         <em>
          IDH1
         </em>
         ) or less commonly
         <em>
          IDH2
         </em>
         ; mutations in the chromatin regulator gene,
         <em>
          ATRX
         </em>
         ; and inactivation of the
         <em>
          TP53
         </em>
         tumor suppressor gene. (See
         <a class="local">
          'TP53 gene'
         </a>
         above and
         <a class="local">
          'Isocitrate dehydrogenase (IDH) gene'
         </a>
         above and
         <a class="local">
          'ATRX gene'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oligodendroglioma formation
         </strong>
         – The hallmark genetic aberration in oligodendroglial tumors is codeletion of chromosomal arms 1p and 19q, present in the majority of pure oligodendrogliomas. Together with mutations in
         <em>
          IDH1/2
         </em>
         , 1p/19q codeletion is a defining and early event in tumorigenesis. Tumor suppressor genes identified on the missing chromosomal arms include the capicua transcriptional repressor (
         <em>
          CIC
         </em>
         ) gene on chromosome 19q and far upstream element binding protein 1 (
         <em>
          FUBP1
         </em>
         ) on chromosome 1p. (See
         <a class="local">
          'Formation of oligodendroglial tumors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          High-grade glioma formation and transition
         </strong>
         – Multiple tumorigenic events are involved in the development of high-grade gliomas such as glioblastoma, including loss of cell cycle control, dysregulation of apoptosis, growth factor overexpression, and angiogenesis via both genetic and epigenetic aberrations. Alkylating agent chemotherapy induces a hypermutation phenotype in high-grade diffuse gliomas, at least partly as a result of defects in mismatch repair. (See
         <a class="local">
          'Formation of glioblastoma and transition from low-grade to high-grade glioma'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pediatric diffuse gliomas
         </strong>
         –
         <strong>
         </strong>
         Pediatric-type gliomas (mostly occurring in children but also sometimes in young adults) are genetically distinct from their adult counterparts, despite similar histopathology  (
         <a class="graphic graphic_table graphicRef134980" href="/z/d/graphic/134980.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Pediatric diffuse gliomas'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In pediatric-type low-grade astrocytomas, duplication of the tyrosine kinase domain of the fibroblast growth factor receptor 1 (
         <em>
          FGFR1
         </em>
         ) gene has been identified in approximately one-quarter of tumors, leading to downstream pathway activation. (See
         <a class="local">
          'Pediatric-type diffuse low-grade gliomas'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In pediatric glioblastoma as well as diffuse intrinsic pontine glioma, recurrent mutations in genes affecting histones and chromatin regulators have been identified in a significant minority of tumors that appear to be important pathogenic events. Those with histone H3 K27M mutations in the brainstem, thalamus, and spinal cord are referred to as "diffuse midline glioma, H3 K27M-mutant." (See
         <a class="local">
          'Pediatric-type diffuse high-grade gliomas'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021; 23:1231.
          </a>
         </li>
         <li class="breakAll">
          Central Nervous System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, 2021.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JH, Lee JE, Kahng JY, et al. Human glioblastoma arises from subventricular zone cells with low-level driver mutations. Nature 2018; 560:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004; 64:7011.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004; 432:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tirosh I, Venteicher AS, Hebert C, et al. Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. Nature 2016; 539:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Venteicher AS, Tirosh I, Hebert C, et al. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science 2017; 355.
          </a>
         </li>
         <li class="breakAll">
          James CD, Louis DN, Cavenee WK. Molecular biology of central nervous system tumors. In: Cancer: Principles and Practice of Oncology, 8th, DeVita VT, Lawrence TS, Rosenberg SA (Eds), Lippincott-Raven, Philadelphia 2008.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol 2006; 1:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suzuki H, Aoki K, Chiba K, et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 2015; 47:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weller M, Weber RG, Willscher E, et al. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol 2015; 129:679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stemmer-Rachamimov AO, Louis DN, Nielsen GP, et al. Comparative pathology of nerve sheath tumors in mouse models and humans. Cancer Res 2004; 64:3718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhu Y, Guignard F, Zhao D, et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 2005; 8:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel AP, Tirosh I, Trombetta JJ, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 2014; 344:1396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riemenschneider MJ, Mueller W, Betensky RA, et al. In situ analysis of integrin and growth factor receptor signaling pathways in human glioblastomas suggests overlapping relationships with focal adhesion kinase activation. Am J Pathol 2005; 167:1379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Snuderl M, Fazlollahi L, Le LP, et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 2011; 20:810.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neftel C, Laffy J, Filbin MG, et al. An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell 2019; 178:835.
          </a>
         </li>
         <li class="breakAll">
          Pathology and genetics of tumours of the nervous system. In: World Health Organization Classification of Tumours of the Nervous System, Editorial and Consensus Conference Working Group, Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), IARC Press, Lyon, France 2007.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321:1807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 2015; 372:2481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunn GP, Rinne ML, Wykosky J, et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 2012; 26:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18:553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010; 17:510.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012; 483:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flavahan WA, Drier Y, Liau BB, et al. Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature 2016; 529:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bunse L, Pusch S, Bunse T, et al. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nat Med 2018; 24:1192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao S, Lin Y, Xu W, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009; 324:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360:765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009; 27:4150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009; 27:5743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 2010; 16:1597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiao Y, Killela PJ, Reitman ZJ, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 2012; 3:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kannan K, Inagaki A, Silber J, et al. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget 2012; 3:1194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu XY, Gerges N, Korshunov A, et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 2012; 124:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abedalthagafi M, Phillips JJ, Kim GE, et al. The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas. Mod Pathol 2013; 26:1425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watanabe K, Tachibana O, Sata K, et al. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996; 6:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006; 66:9852.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 2006; 65:988.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yip S, Butterfield YS, Morozova O, et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol 2012; 226:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bettegowda C, Agrawal N, Jiao Y, et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 2011; 333:1453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 2013; 110:6021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 2015; 372:2499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barthel FP, Johnson KC, Varn FS, et al. Longitudinal molecular trajectories of diffuse glioma in adults. Nature 2019; 576:112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cahill DP, Levine KK, Betensky RA, et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 2007; 13:2038.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shirahata M, Ono T, Stichel D, et al. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathol 2018; 136:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ueki K, Ono Y, Henson JW, et al. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 1996; 56:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujisawa H, Kurrer M, Reis RM, et al. Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter. Am J Pathol 1999; 155:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275:1943.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parker BC, Annala MJ, Cogdell DE, et al. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Invest 2013; 123:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh D, Chan JM, Zoppoli P, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012; 337:1231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rheinbay E, Suvà ML, Gillespie SM, et al. An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma. Cell Rep 2013; 3:1567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brat DJ, Mapstone TB. Malignant glioma physiology: cellular response to hypoxia and its role in tumor progression. Ann Intern Med 2003; 138:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brat DJ, Van Meir EG. Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest 2004; 84:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brat DJ, Castellano-Sanchez AA, Hunter SB, et al. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 2004; 64:920.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maxwell PH, Pugh CW, Ratcliffe PJ. Activation of the HIF pathway in cancer. Curr Opin Genet Dev 2001; 11:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455:1061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang J, Cazzato E, Ladewig E, et al. Clonal evolution of glioblastoma under therapy. Nat Genet 2016; 48:768.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson BE, Mazor T, Hong C, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 2014; 343:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi S, Yu Y, Grimmer MR, et al. Temozolomide-associated hypermutation in gliomas. Neuro Oncol 2018; 20:1300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Touat M, Li YY, Boynton AN, et al. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature 2020; 580:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu Y, Villanueva-Meyer J, Grimmer MR, et al. Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. Neuro Oncol 2021; 23:1872.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Houillier C, Lejeune J, Benouaich-Amiel A, et al. Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer 2006; 106:2218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang J, Wu G, Miller CP, et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 2013; 45:602.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellison DW, Hawkins C, Jones DTW, et al. cIMPACT-NOW update 4: Diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation. Acta Neuropathol 2019; 137:683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012; 482:226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu G, Broniscer A, McEachron TA, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 2012; 44:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sturm D, Witt H, Hovestadt V, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012; 22:425.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5223 Version 37.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34185076" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34185076" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30069053" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Human glioblastoma arises from subventricular zone cells with low-level driver mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15466194" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15549107" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Identification of human brain tumour initiating cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27806376" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28360267" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28360267" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18039109" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Molecular pathology of malignant gliomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25848751" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Mutational landscape and clonal architecture in grade II and III gliomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25783747" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15150133" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Comparative pathology of nerve sheath tumors in mouse models and humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16098465" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24925914" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16251422" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : In situ analysis of integrin and growth factor receptor signaling pathways in human glioblastomas suggests overlapping relationships with focal adhesion kinase activation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22137795" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31327527" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31327527" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18772396" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : An integrated genomic analysis of human glioblastoma multiforme.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26061751" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22508724" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Emerging insights into the molecular and cellular basis of glioblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19935646" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21130701" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20399149" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22343889" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26700815" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Insulator dysfunction and oncogene activation in IDH mutant gliomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29988124" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19359588" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19228619" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : IDH1 and IDH2 mutations in gliomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19636000" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19805672" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20160062" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22869205" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23104868" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22886134" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23765250" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8864278" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17047046" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17021403" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22072542" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21817013" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Mutations in CIC and FUBP1 contribute to human oligodendroglioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23530248" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26061753" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31748746" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Longitudinal molecular trajectories of diffuse glioma in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17404084" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29687258" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8548755" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10433932" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9072974" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23298836" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22837387" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Transforming fusions of FGFR and TACC genes in human glioblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23707066" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12693889" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Malignant glioma physiology: cellular response to hypoxia and its role in tumor progression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14990981" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14871821" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11377966" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Activation of the HIF pathway in cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18772890" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27270107" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Clonal evolution of glioblastoma under therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24336570" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29452419" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Temozolomide-associated hypermutation in gliomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32322066" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Mechanisms and therapeutic implications of hypermutation in gliomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33823014" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20129251" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16568472" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Prognostic impact of molecular markers in a series of 220 primary glioblastomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23583981" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30848347" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22286061" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22286216" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23079654" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
